For example, a phase I trial of the first-generation HSP90 inhibitor 17-AAG in combination with trastuzumab has shown a positive profile in trastuzumab-refractory HER2-overexpressing breast cancer (Modi et al., 2007; Raja et al., 2008). The gene discussed is ERBB2; the disease is breast carcinoma.